Sino Biopharmaceutical (1177) Stock Overview
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
1177 passed our risk checks.
1177 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Sino Biopharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.40 |
| 52 Week High | HK$9.12 |
| 52 Week Low | HK$2.67 |
| Beta | 0.70 |
| 1 Month Change | -12.53% |
| 3 Month Change | 10.61% |
| 1 Year Change | 103.30% |
| 3 Year Change | 82.27% |
| 5 Year Change | -5.49% |
| Change since IPO | 27,147.96% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Sino Biopharmaceutical Limited's (HKG:1177) 31% Share Price Surge
Aug 04
Sino Biopharmaceutical Limited (HKG:1177) Stocks Shoot Up 38% But Its P/E Still Looks Reasonable
Jun 13Sino Biopharmaceutical (HKG:1177) Is Increasing Its Dividend To CN¥0.04
May 23Sino Biopharmaceutical's (HKG:1177) Earnings Seem To Be Promising
May 06Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year
Apr 30Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Apr 27Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04
Apr 06Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04
Mar 23Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult
Jan 13Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?
Dec 08Shareholder Returns
| 1177 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0.3% | -2.0% | 0.6% |
| 1Y | 103.3% | 51.6% | 28.9% |
Return vs Industry: 1177 exceeded the Hong Kong Pharmaceuticals industry which returned 51.6% over the past year.
Return vs Market: 1177 exceeded the Hong Kong Market which returned 28.9% over the past year.
Price Volatility
| 1177 volatility | |
|---|---|
| 1177 Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 1177 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1177's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 23,056 | Eric Tse | www.sinobiopharm.com |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand.
Sino Biopharmaceutical Limited Fundamentals Summary
| 1177 fundamental statistics | |
|---|---|
| Market cap | HK$132.82b |
| Earnings (TTM) | HK$4.25b |
| Revenue (TTM) | HK$33.36b |
Is 1177 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1177 income statement (TTM) | |
|---|---|
| Revenue | CN¥30.57b |
| Cost of Revenue | CN¥5.57b |
| Gross Profit | CN¥24.99b |
| Other Expenses | CN¥21.10b |
| Earnings | CN¥3.90b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.22 |
| Gross Margin | 81.77% |
| Net Profit Margin | 12.75% |
| Debt/Equity Ratio | 25.9% |
How did 1177 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/21 09:22 |
| End of Day Share Price | 2025/10/21 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sino Biopharmaceutical Limited is covered by 52 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Jing Qiang | China International Capital Corporation Limited |